A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies

Inclusion Criteria: * ECOG performance status of 0 to 1. * Life expectancy of more than 12 weeks. * At least one measurable lesion exists.(RECIST 1.1). * Subjects diagnosed with advanced solid malignancies who are refractory to standard therapies or for which no standard therapy exists. * Subjects who have overall good overall general condition. * Signed informed consent. Exclusion Criteria: * Subjects who received any previous treatment with a PARP inhibitor. * Less than 4 weeks from the last clinical trial. * Less than 4 weeks from the last radiotherapy, chemotherapy, surgery, hermone treatment and target therapy. * Subjects that are unable to swallow, or dysfunction of gastrointestinal absorption. * Subjects with symptomatic uncontrolled brain metastases. * Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry. * Subjects with a known hypersensitivity to Fluzoparib or any of the excipients of the product. * Ongoing infection (determined by investigator). * History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation. * Subjects who can not interrupt the using of the drugs that may cause QT prolongation during study. * Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial. * Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test.